TradingKey

Enveric Biosciences, Inc. (ENVB) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 Enveric Biosciences Reports Financial Results and Provides Corporate Update for Second Quarter 2026 EB-003 Development Highlights: ● Continued advancing IND-enabling studies supporting the planned submission of an Investigational New Drug

The Pentagon signed seven-year framework agreements with Boeing and RTX to expand production of Standard Missile-3 components for SM-3 Block IB and Block IIA, including avionics and ejector assemblies Boeing supplies to Raytheon. The deals aim to stabilize supply chains and expand munitions output. Separately, the Missile Defense Agency awarded Raytheon a $745 million contract for Block IIA interceptors.

BrainStorm Cell Therapeutics (OTCQB: BCLI) reported Q2 2026 results for the quarter ended June 30, 2026. It said it is preparing to start the Phase 3b ENDURANCE study of NurOwn in ALS under an FDA-agreed Special Protocol Assessment, planning about 200 patients. Cash was about $0.2M vs $1.03M a year earlier, with Q2 net loss about $3.9M. The company appointed Peter J. Pitts as Executive Chairman and raised about $400k in private placements.

A $116 million Coldcard hardware wallet exploit renewed scrutiny of self-custody as US spot Bitcoin ETFs saw about $1 billion in net inflows for the week, according to Bloomberg. Strategy CEO Phong Le said Strategy will resume Bitcoin accumulation later this year; Riot Platforms reported a 20-year $9 billion compute deal with Anthropic. Trump Media plans to revamp its crypto treasury after a $238 million Q2 net loss.

Rocket Lab says the U.S. Space Force awarded it a $397 million contract under the SB-AMTI program to design, manufacture and launch a fleet of “Flatellites” for real-time airborne threat tracking. The company cites prior 2026 U.S. defense awards totaling $943 million. Rocket Lab also highlighted its GHOST deployable launch system for responsive missions.

Reuters reports Unifor received notice from Stellantis that it is considering selling its Brampton, Ontario plant. Brampton closed for retooling in 2024, was to reopen in 2025 for Jeep Compass, but production shifted to Illinois after Trump tariffs. Unifor contract talks with Stellantis cover Brampton, Windsor and Etobicoke; current contract expires Sept. 20.